Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3531750 | 1.00 | CA2 (0.36) | CA2CHKAKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL901971 | 0.97 | CA2 (0.32) | CA2CHKAKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL1513130 | 0.93 | ALDH1A1 (0.43) | CA2CHKAKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL1256068 | 0.86 | ALDH1A1 (0.37) | SMN1; SMN2 | |
| SCHEMBL336574 | 0.85 | CA2 (0.46) | CA2CHKAKDM4EUSP2SMN1; SMN2 | |
| SCHEMBL4243756 | 0.85 | — | — | |
| SCHEMBL5549254 | 0.85 | HIF1A (0.31) | CA2 | |
| SCHEMBL232289 | 0.85 | — | — | |
| SCHEMBL29883467 | 0.82 | ALDH1A1 (0.39) | SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28035808 | 0.82 | KDM4E (0.44) | CA2CHKAKDM4EUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | CA2 927/4885CHKA 899/4885KDM4E 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.